ReEmerge Raises $37M Series A for Neuromodulation Therapy in Chronic TBI

ReEmerge, a private MedTech company developing neuromodulation technology for brain injury, has raised a $37 million Series A round. The financing was led by U.S. Venture Partners (USVP), with participation from Oxford Science Enterprises, The Vertical Group, Santé Ventures, 415 Capital, IAG Capital Partners, and Dendrion Ventures.

What ReEmerge Does

ReEmerge is developing Cognitive Network Restoration Therapy (CNRT), an investigational neuromodulation approach that targets neural networks in the central thalamus disrupted by brain injury. The therapy is designed to drive underactive but viable circuits, with the goal of reversing chronic cognitive deficits rather than compensating for them.

The technology builds on central thalamic deep brain stimulation research conducted by Nicholas Schiff and colleagues at Weill Cornell Medicine. ReEmerge is advancing the program under an exclusive licensing agreement with Cornell University.

First Clinical Indication

The company's first clinical indication is chronic moderate-to-severe traumatic brain injury. According to the company, a prospective multicenter clinical study is being prepared.

Round Details

• Round type: Series A
• Amount raised: $37,000,000
• Currency: USD
• Lead investor: U.S. Venture Partners (USVP)
• Additional investors: Oxford Science Enterprises, The Vertical Group, Santé Ventures, 415 Capital, IAG Capital Partners, Dendrion Ventures

Why This Matters for the MedTech Landscape

The Series A places ReEmerge among a small group of companies pursuing neuromodulation for cognitive restoration rather than symptom compensation. The distinction is central to the company's positioning: CNRT is described as targeting the underlying disrupted neural networks in the central thalamus, a region implicated in cognitive function following brain injury.

The scientific foundation of the approach traces to academic research at Weill Cornell Medicine, and the exclusive licensing agreement with Cornell University gives ReEmerge a defined pathway to develop and commercialize the technology.

Chronic moderate-to-severe traumatic brain injury represents a patient population with significant unmet need, and the company's planned prospective multicenter clinical study will be a key milestone to watch as the program advances.

What to Watch Next

With the Series A in place, the immediate focus for ReEmerge is the preparation of its prospective multicenter clinical study in chronic moderate-to-severe traumatic brain injury. Progress on that study, along with any further development milestones for the CNRT platform, will shape the company's trajectory in the neuromodulation space.

For investors and strategic partners tracking neuromodulation and brain injury therapeutics, ReEmerge's combination of an academically rooted technology, an exclusive Cornell license, and a well-supported Series A makes it a company to monitor.